Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

By sjmartinez • October 28, 2022

Choudhary MC, Chew KW, Deo R, Flynn JP, Regan J, Crain CR, Moser C, Hughes MD, Ritz J, Ribeiro RM, Ke R, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Fletcher CV, Daar ES, Wohl DA, Eron JJ, Currier JS, Parikh UM, Sieg SF, Perelson AS, Coombs RW, Smith DM, Li JZ; ACTIV-2/A5401 Study Team. Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial. Nat Microbiol. 2022 Nov;7(11):1906-1917. doi: 10.1038/s41564-022-01254-1. Epub 2022 Oct 26. PMID: 36289399.

Tags: Infectious Diseases, Publications

Related Posts

PenA Alleles Associated With Gonococcal Ceftriaxone Resistance in Cambodia, China, and Vietnam

van der Veen S, Sun X, Ge H, Chau TM, Nhung PH, Vandelannoote K, Delvallez G, Cheng S, Laumen JGE, Adamson PC. PenA Alleles Associated[...]

Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance: A Retrospective Study in Hanoi, Vietnam

Adamson PC, David HM, Pham LQ, Bui HTM, Le HHL, Pham QH, Le DH, Giang LM, Klausner JD. Cefixime for the Treatment of Neisseria gonorrhoeae[...]

cGAS-STING dependent type I IFN reduces Leptospira interrogans renal colonization in mice

Gupta S, Matsunaga J, Ratitong B, Manion A, Ismaeel S, Valadares DG, West AP, Kerur N, Stehlik C, Dorfleutner A, Dagvadorj J, Coburn J, Wolf[...]